Price Alert

Anika Therapeutics Inc. (ANIK)

NASDAQ: ANIK · Real-Time Price · USD

8.63

-0.45 (-4.96%)

At close: Aug 14, 2025, 3:59 PM

8.75

1.39%

After-hours: Aug 14, 2025, 05:55 PM EDT

Anika Therapeutics Statistics

Share Statistics

Anika Therapeutics has 14.42M shares outstanding. The number of shares has increased by -3.08% in one year.

Shares Outstanding	14.42M
Shares Change (YoY)	-3.08%
Shares Change (QoQ)	1.17%
Owned by Institutions (%)	85.38%
Shares Floating	13.72M
Failed to Deliver (FTD) Shares	25
FTD / Avg. Volume	0.02%

Short Selling Information

The latest short interest is 323.69K, so 2.26% of the outstanding shares have been sold short.

Short Interest	323.69K
Short % of Shares Out	2.26%
Short % of Float	2.65%
Short Ratio (days to cover)	2.04

Valuation Ratios

The PE ratio is -4.3 and the forward PE ratio is -19.73. Anika Therapeutics's PEG ratio is 0.13.

PE Ratio	-4.3
Forward PE	-19.73
PS Ratio	2.02
Forward PS	1
PB Ratio	1.57
P/FCF Ratio	-103.95
PEG Ratio	0.13

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Anika Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.17.

Current Ratio	4.88
Quick Ratio	3.85
Debt / Equity	0.17
Debt / EBITDA	8.59
Debt / FCF	-11.12
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$416.34K
Profits Per Employee	$-195.78K
Employee Count	288
Asset Turnover	0.59
Inventory Turnover	1.84

Taxes

Income Tax	6.06M
Effective Tax Rate	-219.39%

Stock Price Statistics

The stock price has increased by -67.17% in the last 52 weeks. The beta is 0.64, so Anika Therapeutics's price volatility has been higher than the market average.

Beta	0.64
52-Week Price Change	-67.17%
50-Day Moving Average	10.7
200-Day Moving Average	14.91
Relative Strength Index (RSI)	30.47
Average Volume (20 Days)	108,196

Income Statement

In the last 12 months, Anika Therapeutics had revenue of 119.91M and earned -56.38M in profits. Earnings per share was -3.83.

Revenue	119.91M
Gross Profit	76M
Operating Income	-5.1M
Net Income	-56.38M
EBITDA	3.02M
EBIT	-5.1M
Earnings Per Share (EPS)	-3.83

Full Income Statement

Balance Sheet

The company has 55.63M in cash and 25.93M in debt, giving a net cash position of 29.7M.

Cash & Cash Equivalents	55.63M
Total Debt	25.93M
Net Cash	29.7M
Retained Earnings	71.67M
Total Assets	190.6M
Working Capital	84.61M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.4M and capital expenditures -7.73M, giving a free cash flow of -2.33M.

Operating Cash Flow	5.4M
Capital Expenditures	-7.73M
Free Cash Flow	-2.33M
FCF Per Share	-0.16

Full Cash Flow Statement

Margins

Gross margin is 63.38%, with operating and profit margins of -4.25% and -47.02%.

Gross Margin	63.38%
Operating Margin	-4.25%
Pretax Margin	-2.31%
Profit Margin	-47.02%
EBITDA Margin	2.52%
EBIT Margin	-4.25%
FCF Margin	-1.94%

Dividends & Yields

ANIK does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ANIK is $15, which is 82.3% higher than the current price. The consensus rating is "Buy".

Price Target	$15
Price Target Difference	82.3%
Analyst Consensus	Buy
Analyst Count	1

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	3
Piotroski F-Score	3